Background Actinic keratosis is the most prevalent premalignant skin disorder in the white population.Current guidelines provide no clear recommendations about preferred treatments.Methods The parameters; effectiveness, treatment duration, recurrence, side effects and cost of treatment were investigated for three frequently used topical therapies which were then compared with a most recent developed topical therapy.Published clinical data obtained from the literature was used to compare these parameters for 5-fluorouracil, imiquimod and diclofenac and relate them with the newly developed Curaderm.Results A wide variation in the concentrations of the active anti-keratotic ingredients, application frequency, duration of treatment, recurrence rates and cost of treatment exist between the different topical therapies.The efficacy rates and side effects were less variable.Overall, Curaderm is the most suitable treatment for actinic keratosis.Clinical evidence is presented illustrating the effects of Curaderm on field-directed treatments and solitary treatments of actinic keratoses.Conclusions Current medical guidelines do not provide clear recommendations on which treatment approach for actinic keratosis is preferred.Direct head-to-head comparison between treatments with emphasis on efficacy, safety, treatment duration, compliance, convenience, cosmetic outcome, patient acceptance and cost should be available to the patient, the practising physician, healthcare system and should assist in therapeutic treatment guidelines and policymaking.Given the very favourable profiles of these parameters with Curaderm when compared with other home-based treatments, it should be considered that Curaderm is first-in-line.

Background: Psoriasis is a chronic disease that can have significant effects on quality of life.Aim: To test whether the antineoplastic, antipathogenic plant derived secondary metabolites, solasodine glycosides, can treat psoriasis.Case Presentation: We report a case of a 54-year-old French-Vietnamese male who presented with diagnosed erythematous scaly annular recalcitrant psoriasis scattered throughout his body.Method: After failing conventional treatment regimens for over 10 years the patient received a trial with a topical cream formulation Psorend BEC , containing solasodine glycosides, for his psoriasis.Result: Topical applications of Psorend BEC twice daily resulted in complete resolution of cutaneous lesions after 4 weeks of treatment with no recurrence post 1 year after therapy.Conclusion: Topical Psorend BEC therapy rapidly removes recalcitrant psoriasis with no apparent side effects.

Cancer remains a major cause of mortality worldwide.Progresses have been made in the understanding of the molecular basis of cancer, cancer detection, and cancer treatment.Important strides by treating early-stage cancers have resulted in improved outcomes.Despite these achievements, mortality of cancer patients is high and still there is no cure.Some oncologists remain optimistic that cytotoxic chemotherapy will significantly improve cancer survival.However, notwithstanding the use of new and expensive single and more recently, combination drugs, the improvement of the response rates remains very low.In the United States, cancer death rates decreased by a mere 1.4% to 1.8% from 2004 to 2013.Compared to other serious diseases, the improvement of the cancer patient has been disappointingly lagging, and by far, most patients with advanced cancer eventually die of their disease.The need for improved cancer therapies is self-evident.This communication gives an overview of the overwhelming resurgence of solasodine and its glycosides in cancer therapy.

Atherosclerosis is the primary pathophysiological cause of heart disease and cerebrovascular disease.It is responsible for more than 20% of deaths worldwide each year.Treatments for atherosclerosis may include lifestyle changes, drugs, and medical procedures or surgery.There is a need for a rapid and effective treatment for this disease.In 1976, it was hypothesized that a multifunctional plasma delipidation process when applied to hyperlipidemic patients would lead to rapid regression of atherosclerosis.The procedure has now been applied to a variety of nonprimates, primates and humans.In all models studied, large quantities of antiatherogenic lipoprotein particles were generated that led to the mechanisms of reverse cholesterol transport.Trends to regression and actual regression of atherosclerosis have now been reported using a specific plasma delipidation process consisting of lipid extraction from plasma with mixtures of butanol and ethers.

Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma is the most frequent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause disfigurement with destruction of soft conjunctival tissue. Many therapeutic methods have been recommended to combat the morbidity and mortality associated with these lesions. Excisions with frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for periocular basal cell and squamous cell carcinomas. However, these treatment modalities have various limitations and reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a cream formulation CuradermBEC5 are specific, effective and safe treatments for nonmelanoma skin cancers with excellent cosmesis. The antineoplastic mode of action is by apoptosis. In this review it is shown that CuradermBEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.

In the last century, the discovery of cytotoxic agents was revolutionary for anticancer therapy.These therapies have resulted in better understanding of cancer in general.However, the development of agents that combine efficacy, safety and convenience remains a great challenge.The narrow, if not adverse, therapeutic index of most drugs, the damage not only to cancer cells, but also to normal and healthy tissue and the occurrence of resistance have limited anticancer efficacy.This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.

Background: Untreated actinic keratosis can advance to squamous cell carcinoma, which in turn is associated with a risk of metastasis. Current treatments for actinic keratosis have many shortcomings. This communication describes the efficacy and safety of a topical cream therapy, CuradermBEC5, containing solasodine glycosides (0.005%) for actinic keratosis.Methods: Randomly assigned patients with actinic keratosis on the face, trunk or extremities received so-lasodine glycosides cream (CuradermBEC5) or placebo (vehicle) that was self-applied to the lesions and covered with an occlusive dressing (micropore) twice daily for 3 consecutive days. Complete clearance and local reactions were as-sessed at 56 days with follow-up periods of 6 months and 1 year. Results: The rate of complete clearance at day 56 was higher with solasodine glycosides than with placebo (92% vs. 38%, P 0.001). The absolute success rates after 1 year follow-up were 82% for solasodine glycosides and 18% for placebo. No differences in local reactions were obtained when solasodine glycosides and placebo were compared. Local reactions in both groups peaked at days 2 and 3 with local pain as the major event. The pain associated with treatments lasted approximately 10 minutes after application of solasodine glycosides and placebo. Complete reepithelialization occurred two weeks after treatment. Adverse events were generally mild to moderate in intensity and resolved without sequelae. Conclusions: Solasodine glycosides cream applied topically twice daily with a dressing for 3 days is effective for the treatment of actinic keratoses.

Solasodine rhamnosyl glycosides (SRGs) are chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation, CuradermBEC5, is very effective for the treatment of nonmelanoma skin cancers with excellent cosmetic end results. Intralesion injection of SRGs successfully dispose of very large tumours in animals without any clinical adverse effects. The mode of action of SRGs is by apoptosis. In this study, it is shown that small to large basal cell carcinomas are effectively treated only with topical application of CuradermBEC5. Here it is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime. Two intralesion injections of very low doses of SRGs rapidly and effectively remove a large melanoma on a horse. If rapid removal of large troublesome skin cancers is required then this can be achieved by intralesion and topical treatments. Intralesion or combination therapy with SRGs may have some applications for melanomas in situ such as lentigo maligna.

Solasodine rhamnosyl glycosides (BEC) are a new class of antineoplastics that show superior efficacy than many established anticancer drugs as shown by intravenous, intraperitoneal and intralesion administrations. Previous studies have described the efficacy of BEC on nonmelanoma skin cancers by topical application. Two cases are now reported which show that BEC in a cream formulation Curaderm is very effective for the treatment of large nonmelanoma skin cancers that are considered difficult to treat by existing modalities. Moreover, the cosmetic outcomes are very impressive.

Australian and New Zealand Journal of MedicineVolume 10, Issue 1 p. 130-130 ANALGESIC-INDUCED RENAL PAPILLARY NECROSIS AND SALICYLATE METABOLISM IN THE GUNN RAT Roy A. Axelsen, Roy A. Axelsen Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorFelix Bochner, Felix Bochner Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorVeronica E. Cartwright, Veronica E. Cartwright Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorDebra M. Imhoff, Debra M. Imhoff Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorBill E. Cham, Bill E. Cham Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this author Roy A. Axelsen, Roy A. Axelsen Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorFelix Bochner, Felix Bochner Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorVeronica E. Cartwright, Veronica E. Cartwright Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorDebra M. Imhoff, Debra M. Imhoff Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this authorBill E. Cham, Bill E. Cham Departments of Pathology and Medicine, University of QueenslandSearch for more papers by this author First published: February 1980 https://doi.org/10.1111/j.1445-5994.1980.tb03501.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. Volume10, Issue1February 1980Pages 130-130 RelatedInformation